Brands
Malabar unveils 15th Brides of India campaign celebrating culture
Mumbai: Malabar Gold and Diamonds has launched the 15th edition of its flagship brides of India campaign, one of the country’s biggest bridal showcases and a celebration of the diversity, emotion and memory woven into Indian weddings. This year’s chapter brings together 22 brides and 10 well-known celebrities including Alia Bhatt, Kareena Kapoor Khan, NTR, Karthi, Anil Kapoor and Srinidhi Shetty.
Directed by Abhishek Varman with music by Shubhajit Mukherjee, the new brand film captures the many worlds an Indian bride carries with her, from rituals and roots to the jewellery that becomes part of her identity.
For Malabar Gold and Diamonds, the campaign marks a major milestone in its long commitment to bridal craftsmanship. Chairman M. P. Ahammed said the 15th edition continues the brand’s tribute to Indian brides, honouring traditions while recognising personal expression. He added that Malabar’s focus on transparency and quality aims to give families confidence in choosing jewellery that is both meaningful and trustworthy.
The collection spans every corner of the country, from Rajasthani polki craftsmanship and Tamil Nadu’s temple-inspired gold to Kerala’s kasavu-influenced bridal pieces and Bengal’s intricate motifs. Malabar’s design depth means a bride in any city can choose jewellery from any cultural style, whether a Chennai bride seeking regal polki or a Delhi bride embracing South Indian temple work.
The 2025 line features the Divine Collection inspired by heritage and temple art, the gemstone-rich Precia Collection, and a contemporary Diamond Collection that blends modern elegance with traditional motifs. Every piece is crafted by Malabar’s master artisans to honour rituals, culture and the auspicious moments surrounding a wedding.
Celebrities associated with the campaign echoed its emotional appeal. Alia Bhatt said the campaign showcases how brides bring their own personality into tradition, while Kareena Kapoor Khan praised its sincerity in bringing cultural stories together. Anil Kapoor highlighted how the jewellery reflects both celebration and the quiet emotion at the heart of a wedding.
With its latest edition, Malabar Gold and Diamonds reinforces its position as a leading bridal destination, offering gold, diamond, platinum and gemstone designs that reflect India’s cultural richness. The brand invites brides to explore jewellery that speaks to their heritage, their identity and the memories they will carry forward.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
